Gilead hepatitis C drug meets goal of fourth late-stage study

[riky]

Gilead hepatitis C drug meets goal of fourth late-stage study

<p><a href="http://news.yahoo.com/gileads-hep-c-drug-meets-main-goal-fourth-154455725--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/lHCRXKMtgI1u77OhxFv3iQ--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-02-19T182505Z_1_CBRE91I1F5Y00_RTROPTP_2_MARTIN.JPG" width="130" height="86" alt="John Martin, CEO of Gilead, poses before speaking to reporters during the Reuters 2006 Biotechnology.." align="left" title="John Martin, CEO of Gilead, poses before speaking to reporters during the Reuters 2006 Biotechnology.." border="0" /></a>(Reuters) - Gilead Sciences Inc said its experimental hepatitis C drug sofosbuvir, in a late-stage clinical study, was clearly superior to historical cure rates at both 12 and 16 weeks of treatment in patients who were not helped by prior therapy. The cure rate for those with genotype 2 and 3 of the serious liver disease was significantly higher for patients who received 16 weeks of treatment: 73 percent versus 50 percent for those treated for 12 weeks, according to study results released on Tuesday. ...</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login